Clinical Trials Logo

Severe Combined Immunodeficiency clinical trials

View clinical trials related to Severe Combined Immunodeficiency.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT02860559 Not yet recruiting - Clinical trials for Severe Combined Immunodeficiency

Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency

Start date: August 2021
Phase: Phase 1
Study type: Interventional

This is a study of stem cell transplantation with TBX-1400 in pediatric subjects with severe combined immunodeficiency (SCID). The donor cells are exposed to a protein that has been shown in the laboratory to improve the ability of the donor cells to make blood and immune cells after transplant. Exposure of the donor cells to this protein does not modify the genes in the cells in any way. This study has two goals. The first goal is to find out if transplant with TBX-1400 is safe. The second goal is to find out what effects TBX-1400 stem cells have on time to engraftment in pediatric subjects with SCID. The study hypothesis is that TBX-1400 cells will shorten the time to immune reconstitution after transplant.

NCT ID: NCT02231983 Not yet recruiting - Clinical trials for Severe Combined Immunodeficiency

Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China

Start date: September 2014
Phase: N/A
Study type: Observational [Patient Registry]

Severe combined immunodeficiency (SCID), a rare primary immunodeficiency dieases (PID), is poorly characterized in mainland China. We meant to explore the patients with SCID refered to our hospital and summarize their clinical manifestations and genetic features.